Medicus Pharma于2025年12月5日完成认股权交易，筹集了510万美元，并发行了未来股票的新认股权证。 Medicus Pharma completed a warrant deal on Dec. 5, 2025, raising $5.1M and issuing new warrants for future shares.

Medicus Pharma（纳斯达克代码：MDCX）于2025年12月5日宣布完成认股权证诱导交易，立即以每股1.92美元的低价行使所有未偿还的A轮和B轮认股权证。 Medicus Pharma (NASDAQ:MDCX) announced on December 5, 2025, that it completed a warrant inducement deal, leading to the immediate exercise of all outstanding Series A and B Warrants at a reduced price of $1.92 per share. 这从购买2 680 000份共同股份中产生了约510万美元的毛收入。 This generated approximately $5.1 million in gross proceeds from the purchase of 2,680,000 common shares. 作为交换,该公司签发了未注册的C系列和D授权证,额外4 020 000份股份,每股2美元,可在5年半的时间内行使,并准备提交登记表供转售。 In exchange, the company issued unregistered Series C and D Warrants for 4,020,000 additional shares at $2.00 per share, exercisable over five and a half years, with a registration statement expected to be filed for resale. 根据Maxim Group LLC的建议,交易定于2025年12月5日结束,等待惯例条件。 The transaction, advised by Maxim Group LLC, is set to close on December 5, 2025, pending customary conditions. 该公司的重点是开发一个用于巴萨细胞皮肤癌的微针片,继续在美国、欧洲和阿联酋进行第3阶段试验,并正在探索与Helix Nano技术进行MRNA合作的可能性。 The company, focused on developing a microneedle patch for basal cell skin cancer, continues Phase 3 trials in the U.S., Europe, and the UAE, and is exploring a potential mRNA collaboration with Helix Nanotechnologies.